Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Statera Biopharma Inc (STAB)

Statera Biopharma Inc (STAB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Statera Biopharma Announces BF Borgers CPA PC as Independent Registered Public Accounting Firm Globe Newswire - Tue Jun 14, 2022

FORT COLLINS, Colo., June 14, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (NASDAQ: STAB) (the “Company” or “Statera Biopharma”), a biopharmaceutical...

STAB : 0.0001 (unch)
Statera Biopharma Receives Notification Letter from Nasdaq Regarding Form 10-Q Filing Globe Newswire - Mon May 23, 2022

FORT COLLINS, Colo., May 23, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma (Nasdaq: STAB) (the “Company”), a biopharmaceutical company creating...

STAB : 0.0001 (unch)
Statera Biopharma and Lay Sciences Inc. Announce Intent to Enter Strategic Partnership to License the Manufacturing Rights to Certain Lay Sciences IgY Products Globe Newswire - Fri May 13, 2022

Statera expects to acquire option to license Lay Sciences products for respiratory & gastrointestinal disorders ...

STAB : 0.0001 (unch)
Statera Biopharma and Immune Therapeutics Inc. Announce Strategic Agreement for Rights to Low Dose Naltrexone Globe Newswire - Wed Apr 27, 2022

FORT COLLINS, Colo., April 27, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma (Nasdaq: STAB) (the “Company”), a leading biopharmaceutical company creating...

STAB : 0.0001 (unch)
IMUN : 0.0930 (-7.00%)
Statera Biopharma Receives Notification Letter from Nasdaq Regarding Form 10-K Filing Globe Newswire - Fri Apr 22, 2022

FORT COLLINS, Colo., April 22, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma (Nasdaq: STAB) (the “Company”), a biopharmaceutical company creating...

STAB : 0.0001 (unch)
Statera Biopharma and Coeptis Therapeutics Announce Strategic Agreement for Rights to Entolimod Globe Newswire - Wed Apr 13, 2022

FORT COLLINS, Colo., April 13, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma (Nasdaq: STAB) (the “Company”), a biopharmaceutical company creating...

STAB : 0.0001 (unch)
COEP : 0.1899 (-1.96%)
Statera Biopharma, Inc. to Report Fourth Quarter and Full Year 2021 Financial Results on March 31, 2022 Globe Newswire - Mon Mar 28, 2022

Live Conference Call and Webcast at 5:30 p.m. ET FORT COLLINS, Colo., March 28, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (Nasdaq: STAB) (the...

STAB : 0.0001 (unch)
Statera Biopharma Announces Closing of $5.7 Million Underwritten Public Offering Globe Newswire - Thu Mar 24, 2022

FORT COLLINS, Colo., March 24, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (NASDAQ: STAB) (the “Company” or “Statera Biopharma”), a leading...

STAB : 0.0001 (unch)
Statera Biopharma Announces Pricing of $5.7 Million Underwritten Public Offering Globe Newswire - Tue Mar 22, 2022

FORT COLLINS, Colo., March 22, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (NASDAQ: STAB) (the “Company” or “Statera Biopharma”), a leading...

STAB : 0.0001 (unch)
CORRECTION -- Statera Biopharma Announces Proposed Underwritten Public Offering Globe Newswire - Tue Mar 22, 2022

FORT COLLINS, Colo., March 22, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (NASDAQ: STAB) (the “Company” or “Statera Biopharma”), a leading...

STAB : 0.0001 (unch)

Barchart Exclusives

Up 882% YTD, Is It Too Late to Buy This Fintech Stock? Barchart - 7 minutes ago
A recent guidance boost from DAVE propelled the stock even higher. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot